Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl, Katholieke Universiteit Leuven K U Leuven R&DfiledCriticalUcb Biopharma Sprl
Priority claimed from PCT/EP2013/077846external-prioritypatent/WO2014096423A1/en
Publication of MA38279A1publicationCriticalpatent/MA38279A1/en
Publication of MA38279B1publicationCriticalpatent/MA38279B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
Cette invention concerne une série de dérivés de pyrazolo[3,4-d]pyrimidine qui sont substitués à la position 4 par un fragment monocyclique, bicyclique ponté ou spirocyclique de type diaza, qui sont bénéfiques pour traiter et/ou prévenir diverses maladies humaines, comprenant les troubles inflammatoires, autoimmuns et oncologiques ; les maladies virales et le paludisme ; et le rejet de greffes d'organes et de cellules.This invention relates to a series of pyrazolo [3,4-d] pyrimidine derivatives which are substituted at the 4-position by a monocyclic, bridged bicyclic or spirocyclic diaza moiety, which are beneficial for treating and / or preventing various human diseases, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and rejection of organ and cell transplants.
MA38279A2012-12-202013-12-20
Therapeutically active pyrazolo-pyrimidine derivatives
MA38279B1
(en)
N- (GETERO) ARYLPYRROLIDINE DERIVATIVES PYRAZOL-4-ILPYRROLO [2,3-d] PYRIMIDINES AND PYRROL-3-ILPYRROLO [2,3-d] PYRIMIDINES AS AN INITIATORS YANUS-I-I-I-I-I-I-I-I-I-I-I-IU-ZY-3-d)